68 related articles for article (PubMed ID: 15241009)
1. Influence of osteoprotegerin (OPG) on resorption of heterotopically induced ossicle.
Kochanowska I; Włodarski K; Pienkowski M; Ostrowski K
Cell Tissue Bank; 2004; 5(2):125-8. PubMed ID: 15241009
[TBL] [Abstract][Full Text] [Related]
2. Influence of osteoprotegerin (OPG) on experimentally induced ectopic bone.
Włodarski KH; Kochanowska I; Pieńikowski M; Ostrowski K
Folia Biol (Krakow); 2004; 52(3-4):205-9. PubMed ID: 19058561
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
[TBL] [Abstract][Full Text] [Related]
4. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
[TBL] [Abstract][Full Text] [Related]
5. Magnesium deficiency: effect on bone and mineral metabolism in the mouse.
Rude RK; Gruber HE; Wei LY; Frausto A; Mills BG
Calcif Tissue Int; 2003 Jan; 72(1):32-41. PubMed ID: 12370796
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin ameliorates sciatic nerve crush induced bone loss.
Bateman TA; Dunstan CR; Lacey DL; Ferguson VL; Ayers RA; Simske SJ
J Orthop Res; 2001 Jul; 19(4):518-23. PubMed ID: 11518255
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin mitigates tail suspension-induced osteopenia.
Bateman TA; Dunstan CR; Ferguson VL; Lacey DL; Ayers RA; Simske SJ
Bone; 2000 May; 26(5):443-9. PubMed ID: 10773583
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
[TBL] [Abstract][Full Text] [Related]
10. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
[TBL] [Abstract][Full Text] [Related]
12. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
13. Resorption of auditory ossicles and hearing loss in mice lacking osteoprotegerin.
Kanzaki S; Ito M; Takada Y; Ogawa K; Matsuo K
Bone; 2006 Aug; 39(2):414-9. PubMed ID: 16564235
[TBL] [Abstract][Full Text] [Related]
14. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption.
Onyia JE; Galvin RJ; Ma YL; Halladay DL; Miles RR; Yang X; Fuson T; Cain RL; Zeng QQ; Chandrasekhar S; Emkey R; Xu Y; Thirunavukkarasu K; Bryant HU; Martin TJ
J Pharmacol Exp Ther; 2004 Apr; 309(1):369-79. PubMed ID: 14718597
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin and bone mass in squamous cell head and neck cancer patients.
Valero C; Olmos JM; Rivera F; Hernández JL; Vega ME; Macías JG
Calcif Tissue Int; 2006 Jun; 78(6):343-7. PubMed ID: 16830204
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.
Kostenuik PJ; Bolon B; Morony S; Daris M; Geng Z; Carter C; Sheng J
Bone; 2004 Apr; 34(4):656-64. PubMed ID: 15050896
[TBL] [Abstract][Full Text] [Related]
18. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
Koyama H; Nakade O; Takada Y; Kaku T; Lau KH
J Bone Miner Res; 2002 Jul; 17(7):1219-29. PubMed ID: 12096835
[TBL] [Abstract][Full Text] [Related]
19. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Kaji H; Kanatani M; Sugimoto T; Chihara K
Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
[TBL] [Abstract][Full Text] [Related]
20. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury.
Maïmoun L; Couret I; Mariano-Goulart D; Dupuy AM; Micallef JP; Peruchon E; Ohanna F; Cristol JP; Rossi M; Leroux JL
Calcif Tissue Int; 2005 Jun; 76(6):404-11. PubMed ID: 15812577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
